+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Osteoarthritis Pain Drug Market by Drug Class (Corticosteriods, NSAIDs, Viscosupplementation), Route of Administration (Oral, Parenteral, Topical), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4995456
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Osteoarthritis Pain Drug Market size was estimated at USD 8.03 billion in 2023, USD 8.54 billion in 2024, and is expected to grow at a CAGR of 6.47% to reach USD 12.47 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Osteoarthritis Pain Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Osteoarthritis Pain Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Osteoarthritis Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abiogen Pharma Spa, Bayer AG, Bioventus, Eli Lilly and Company, Ferring B.V., GlaxoSmithKline Plc., Horizon Therapeutics plc, Johnson & Johnson Private Limited, Medivir AB, Merck Sharp & Dohme Corp., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the Osteoarthritis Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Corticosteriods
    • NSAIDs
    • Viscosupplementation
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Osteoarthritis Pain Drug Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Osteoarthritis Pain Drug Market?
  3. What are the technology trends and regulatory frameworks in the Osteoarthritis Pain Drug Market?
  4. What is the market share of the leading vendors in the Osteoarthritis Pain Drug Market?
  5. Which modes and strategic moves are suitable for entering the Osteoarthritis Pain Drug Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Osteoarthritis Pain Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of osteoarthritis and growing population susceptible to osteoarthritis
5.1.1.2. Rising number of sports injuries
5.1.1.3. Increasing consumer awareness level and improved technology
5.1.2. Restraints
5.1.2.1. High cost of drug development and severe side-effects
5.1.3. Opportunities
5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
5.1.3.2. Ongoing research and development
5.1.3.3. Collaborations between governments and private companies for the supply of drugs
5.1.4. Challenges
5.1.4.1. Presence of counterfeit and cheap quality drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Osteoarthritis Pain Drug Market, by Drug Class
6.1. Introduction
6.2. Corticosteriods
6.3. NSAIDs
6.4. Viscosupplementation
7. Osteoarthritis Pain Drug Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
7.4. Topical
8. Osteoarthritis Pain Drug Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Osteoarthritis Pain Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Osteoarthritis Pain Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Osteoarthritis Pain Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Abiogen Pharma Spa
13.1.3. Bayer AG
13.1.4. Bioventus
13.1.5. Eli Lilly and Company
13.1.6. Ferring B.V.
13.1.7. GlaxoSmithKline Plc.
13.1.8. Horizon Therapeutics plc
13.1.9. Johnson & Johnson Private Limited
13.1.10. Medivir AB
13.1.11. Merck Sharp & Dohme Corp.
13.1.12. Novartis AG
13.1.13. Pfizer, Inc.
13.1.14. Regeneron Pharmaceuticals, Inc.
13.1.15. Sanofi S.A.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. OSTEOARTHRITIS PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 2. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. OSTEOARTHRITIS PAIN DRUG MARKET DYNAMICS
FIGURE 7. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 10. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 14. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. DENMARK OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. POLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. QATAR OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. OSTEOARTHRITIS PAIN DRUG MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Abiogen Pharma Spa
  • Bayer AG
  • Bioventus
  • Eli Lilly and Company
  • Ferring B.V.
  • GlaxoSmithKline Plc.
  • Horizon Therapeutics plc
  • Johnson & Johnson Private Limited
  • Medivir AB
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information